(Often referred to as Tumor Infiltrating
Lymphocytes/TIL)
Therapies
using TDAC can enhance a patient's
immune system's ability to attack
invading cancer cells... cancer
cells remaining after surgery, radiation
and/or chemotherapy have failed.
TDAC are obtained
by processing a patient's tumor specimen
and separating the lymphocytes from
the cancer cells. These tumor-specific
T-lymphocytes are activated with
the FDA-approved drug, Interleukin-2,
to stimulate cell reproduction
in a bioreactor. After weeks of
closely monitored growth, the resulting
billions of TDAC are harvested into
infusion bags and sent back to the
patient's treatment facility for
infusion.
An average TDAC growth by CTI
produces 1.28 x 1011 cells. (3.2
x 1010 average for each of the
4 infusions).
CTI can provide an established
treatment protocol and nursing
procedure guidelines.
CTI can provide orientation and
training of selected client personnel
if desired.
Dr. Robert K. Oldham is available
to discuss specific patient details.
BENEFITS
Can stimulate the patient's
immune system to attack invading cancer
cells and has the potential to generate
a clinical response.
Enhances the hospital's ability to
participate in clinical trials.
Can
contribute to increasing the hospital's
patient census.
Provides a competitive
advantage for the local treatment facility.
ELIGIBILITY CRITERIA
TDAC therapy
can be considered for patients having
a malignancy, except for those whose
physical or mental condition, in the
opinion of their physician, rule out
cell-related therapies.
Specific emphasis
should be placed on melanoma and renal
cell carcinoma.
Patients requiring
re-operations due to failed treatments
involving surgery, chemotherapy and
radiation therapy are prime candidates
for TDAC.
BILLING
Service
Research
Service Charge
Cryopreservation and Processing
$1,250
TDAC Feasibility
(cannot
occur until after cryopreservation
/ processing)
$2,250
TDAC Growth
(4
infusion treatments)
$11,250
Footnotes:
Average tumor
size cryopreserved is
3.5 grams.
Greater than
80% success rate for
growing TDAC from a
varying range of tumor
types and sizes.
Average
number of lymphocytes
cryopreserved after
completion of a TDAC
Feasibility equals 1.5
x 109.
Average TDAC
growth produces 1.28
x 1011 cells.
(4 infusions at an average
of 3.2 x 1010 cells
each).
Cancer
Therapeutics, Inc.™ (CTI)
is a leader in activated cell technology
offering Tumor Derived Activated Cells
(TDAC).
